Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: FDA Delays Elagolix, Mylan Eyes For Neulasta Biosimilar Approval, And Duvelisib Gets Priority Review

Related Content

Keeping Track: DMD, RMAT, HIV, BTDs, Tc-99m – FTW

Feb 11 2018

Pacira's Exparel Adds Nerve Block Indication For Shoulder Surgery In US

Apr 10 2018

Keeping Track: Delay (For Celgene), Delay (For Allergan), Goose! (Approval For Lilly)

Mar 04 2018

Neulasta Is 4-0 Versus Biosimilars Now That Mylan Has A CRL From FDA

Oct 10 2017

Infinity Doesn't Sugarcoat Disappointing Duvelisib Data

Jun 20 2016

Taking Biosimilars Down A PEG: Why Copying Neulasta Isn’t So Easy

Jun 13 2017

Another Elagolix Study Supports AbbVie's NDA, But Which Dose?

Feb 11 2016

Verastem Sees Phase III Success With PIK3 Inhibitor Dropped By AbbVie

Sep 06 2017

Pacira Sees Big Opportunity In Exparel's Narrow Nerve Block Indication

Apr 10 2018

AbbVie's Got A Competitive Edge With Elagolix For Women With Uterine Fibroids

Feb 21 2018

Related Companies

AbbVie Inc.

Neurocrine Biosciences, Inc.

Viatris Inc.

Biocon, Ltd.

Verastem, Inc.

Novartis AG

Pacira BioSciences, Inc.

Allergan plc

Novartis AG

Coherus Oncology, Inc.

Apotex Inc.

Roche Holding AG

Additional Topics

United States Biosimilars Drug Review Regulation Neurology BioPharmaceutical Cancer

More from Biosimilars

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window